January 3, 2025 01:06 PM EST
Pharma
FDA+

No­vo pe­ti­tions FDA over Vic­toza com­pound­ing as first gener­ic wins ap­proval

Zachary Brennan

Senior Editor

No­vo Nordisk is con­tin­u­ing its cit­i­zen pe­ti­tion cru­sade at the FDA, this time aim­ing to stop the com­pound­ing of Vic­toza, its block­buster GLP-1.

The push …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

A service from the Financial Times